MedTrace Logo

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

NCT07102719 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-05

No results posted yet for this study

Summary

The purpose of this study is to compare the pharmacokinetics and safety of HDP023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers

Conditions

  • Healthy Volunteers

Interventions

DRUG

HD-P023

Single dose administration of HD-P023

DRUG

Teneligliptin and Empagliflozin

Single does administration of Teneligliptin and Empagliflozin High

Sponsors & Collaborators

  • Handok Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-10
Primary Completion
2025-10-20
Completion
2025-10-20

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07102719 on ClinicalTrials.gov